SESSION TITLE: Monday Abstract Posters SESSION TYPE: Original Investigation Posters PRESENTED ON: 10/21/2019 02:30 PM - 03:15 PM PURPOSE: To analyze patterns of drug resistance among Tuberculosis patients in a Tertiary care centre in Mumbai: A Prospective study METHODS: Prospective Descriptive observational study was done over 18 months. A total of 181 Mycobacterium Tuberculosis (MTB) Culture Positive patients were included. DST was done by Bactec MGIT 960. Automated liquid culture systems are recommended by the WHO as the current gold standard for DST. The samples were subjected to DST for the following thirteen drugs with the recommended critical concentrations: Isoniazid, Rifampicin, Pyrazinamide, Ethambutol, Streptomycin, Amikacin, Kanamycin, Capreomycin, Ofloxacin, Moxifloxacin, Ethionamide, Para-aminosalicylic acid, and Clofazimine. A detailed history was taken in the form of a questionnaire which included history, site of TB, past history, antitubercular drugs taken, contact with TB source, previously diagnosed XDR patients were excluded. Sampling was done from pulmonary and extrapulmonary samples for AFB smear and MGIT cultures, and if culture positive DST was done for 13 drugs. The DST results and the patient characteristics were then analyzed. RESULTS: Out of 181 total patients, 83(45.8%) were found to be MDR-TB and 10(5.5%) were XDR-TB. Resistance either to any individual drug or in combination with other drugs was highest for Isoniazid (105, 58.01%), followed by Streptomycin (86, 47.51%), Rifampicin (85, 46.96%), Ethambutol (65, 35.91%), Pyrazinamide (62, 34.25%), Ofloxacin (61, 33.7%), Ethionamide (55, 30.39%), Moxifloxacin (46, 25.41%), Para-aminosalicylic acid (18, 9.94%), Kanamycin (11, 6.08%), Amikacin(10, 5.52%), Capreomycin (10, 5.52%). None of the patients showed resistance to Clofazimine.correlation between XDR-TB and history of previous treatment with anti-TB drugs (p<0.001 by Fischer’s Exact Test). Mean duration of symptoms was 10.5 months for XDR-TB patients as compared to 3.82 months for non XDR-TB patients previously treated cases were significantly higher than new cases among XDR-TB cases compared to non XDR-TB cases. CONCLUSIONS: 1) Out of all drugs, the highest resistance was seen to Isoniazid (58.1%) 2) Ofloxacin resistance (33.7%) was highest among second-line drugs and may be due to inappropriate use of fluoroquinolone as broad-spectrum antibiotics. 3) High resistance to second-line drugs may be due to its widespread and unchecked prescription. 4) Least resistance was seen to second-line aminoglycosides (5.5-6%) 5) No resistance to Clofazimine could probably be due to very little ability of MTB to develop resistance to Clofazimine. CLINICAL IMPLICATIONS: 1. Fluoroquinolones should be used judiciously as shown by our study the highest second-line drug resistance is with fluoroquinolones mostly due to their limitless use as a broad spectrum antibiotic. 2. Isoniazid should not be used with only rifampicin in CP Phase of drug therapy for TB. 3. Clofazimine is a good reserve drug for MDR TB. DISCLOSURES: No relevant relationships by Amita Nene, source=Web Response No relevant relationships by Neel Thakkar, source=Web Response
Read full abstract